An Evolving Understanding of the Basis and Management of Vascular Complications of COVID-19: Where Do We Go From Here?
Pathophysiological mechanisms involved in COVID-19 vascular dysfunction and coagulopathy. During infection, SARS-CoV-2 gains entry to human cells via interaction of its spike protein with the angiotensin-converting enzyme 2 (ACE2) receptor. Downregulation of ACE2 activity, related accumulation of angiotensin-II, and upregulation of the kallikrein-bradykinin pathway with a marked reduction in pericytes through apoptosis of infected cells contribute to the thromboinflammatory process. The diseased endothelium harms vascular integrity with consequent vascular leakage and vasoconstriction that induce ischemia and apoptosis. This leads to macrophage and complement activation, and further leukocyte recruitment. Amplification loops of the inflammatory response ensue, with overproduction of cytokines and immune mediators. At the time of endothelial injury and the consequent inflammatory response, exposure of a thrombogenic basement membrane can trigger coagulation pathways. Activation of the clotting cascade involves recruitment of platelets and release of trophic cytokines and procoagulant mediators, which are further enhanced by the expression of adhesion proteins (including P-selectin, von Willebrand factor, and fibrinogen), increase in tissue factor activity, and suppression of fibrinolysis and thrombomodulin that ultimately results in thrombosis. Elevated inflammatory markers and hematological derangements such as thrombocytopenia and high levels of D-dimer and other fibrin breakdown products correlate with greater mortality risk and adverse outcomes. CRP, C-reactive protein; DVT, deep vein thrombosis; ICAM, intercellular adhesion molecule; IL, interleukin; MI, myocardial infarction; PE, pulmonary embolism; TNF, tumour necrosis factor; VWF, von Willebrand factor.